Rafferty Asset Management, LLC Pmv Pharmaceuticals, Inc. Transaction History

Rafferty Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$8.17 - $12.95 $200,540 - $317,870	-24,546 Reduced 8.48%	264,772 $2.3 Million
Q3 2022 Nov 14, 2022	BUY	$11.4 - $17.18 $563,775 - $849,619	49,454 Added 20.62%	289,318 $3.44 Million
Q2 2022 Aug 12, 2022	BUY	$9.23 - $22.43 $625,461 - $1.52 Million	67,764 Added 39.37%	239,864 $3.42 Million
Q1 2022 May 13, 2022	BUY	$14.86 - $23.55 $801,043 - $1.27 Million	53,906 Added 45.61%	172,100 $3.58 Million
Q4 2021 Feb 10, 2022	BUY	$19.99 - $30.24 $774,512 - $1.17 Million	38,745 Added 48.77%	118,194 $2.73 Million
Q3 2021 Nov 10, 2021	BUY	$26.84 - $36.58 $1.2 Million - $1.64 Million	44,735 Added 128.87%	79,449 $2.37 Million
Q2 2021 Aug 10, 2021	BUY	$28.01 - $36.01 $230,858 - $296,794	8,242 Added 31.13%	34,714 $1.19 Million
Q1 2021 May 10, 2021	BUY	$30.66 - $49.5 $811,631 - $1.31 Million	26,472 New	26,472 $871,000

41.9M

3.1K

1.7K

Ticker PMVP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,622,600
Market Cap $73.5M
Description
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also d...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.